Comparison of the beginning of therapeutic response between different typical and atypical antipsychotics in acute psychosis

Comparison of the velocity of remission of acute psychotic symptoms by different typical and atypical antipsychotics in patients with acute psychosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020326353N1

Enrollment

Registered

2016-12-13

Start date

2016-10-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute psychosis.

Interventions

Intervention 1: Tab aripiprazole 15 mg daily, until onset of drug response according to Positive and Negative Symptom Scale. Intervention 2: Tab risperidone 4 mg daily, until onset of drug response ac

Treatment - Drugs

Tab aripiprazole 15 mg daily, until onset of drug response according to Positive and Negative Symptom Scale

Tab risperidone 4 mg daily, until onset of drug response according to Positive and Negative Symptom Scale

Tab perphenazine 24 mg daily, until onset of drug response according to Positive and Negative Symptom Scale

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 1) 18-60 years aged; 2) onset of psychotic symptoms (delusion, hallucination, thought disorder or bizarre behavior) through 30 days before the study; 3) current diagnosis of schizophrenia, schizophreniform disorder, substance induced psychotic disorder, psychotic disorder due to GMC and psychotic disorder NOS according to DSM-IV-TR criteria; 4) a score of at least four on at least two of the positive subscales or at least five on at least one of the positive subscales of the Positive and Negative Symptoms Scale 5) written informed consent. Exclusion criteria: 1) any serious medical condition that may interfere with safe study participation; 2) receiving any antipsychotic treatment for more than seven days during 30 days before; 3) receiving any long acting antipsychotic through three months before the study; 4) incidence of acute psychosis in context of mood disorders; 5) pregnancy or nursing in women; 6) history of sever drug reaction to the drugs in study; 7) simultaneous use of anticonvulsants, antidepressants or mood stabilizer drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Onset of response to antipsychotic. Timepoint: Eache 2 days. Method of measurement: Positive subscales of Positive and Negative Symptoms Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Alavi

Ahvaz Jundishapur Univesity of Medical Sciences

dr.alavi61@gmail.com+98 613332368

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026